Get started
Marker Therapeutics, Inc.Marker Therapeutics, Inc.Marker Therapeutics, Inc.

Marker Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MRKR chart


Full chart

MRKR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪33.91 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.08 USD
Net income (FY)
‪−16.97 M‬ USD
Revenue (FY)
‪3.31 M‬ USD
Shares float
‪6.45 M‬
Beta (1Y)
1.70

Employees


Employees (FY)
8
Change (1Y)
−59 −88.06%
Revenue / Employee (1Y)
‪413.89 K‬ USD
Net income / Employee (1Y)
‪−1.76 M‬ USD

About Marker Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Juan F. Vera
Website
markertherapeutics.com
Headquarters
Houston
Founded
1991
FIGI
BBG000GMZP09
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRKR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MRKR is 3.80 USD — it has increased by 1.88% in the past 24 hours. Watch Marker Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Marker Therapeutics, Inc. stocks are traded under the ticker MRKR.
MRKR stock has fallen by −18.80% compared to the previous week, the month change is a 17.65% rise, over the last year Marker Therapeutics, Inc. has showed a −0.26% decrease.
We've gathered analysts' opinions on Marker Therapeutics, Inc. future price: according to them, MRKR price has a max estimate of 19.00 USD and a min estimate of 19.00 USD. Watch MRKR chart and read a more detailed Marker Therapeutics, Inc. stock forecast: see what analysts think of Marker Therapeutics, Inc. and suggest that you do with its stocks.
MRKR reached its all-time high on Apr 15, 2003 with the price of 1,080,432.00 USD, and its all-time low was 0.67 USD and was reached on Mar 31, 2023. View more price dynamics on MRKR chart.
See other stocks reaching their highest and lowest prices.
MRKR stock is 8.66% volatile and has beta coefficient of 1.70. Track Marker Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Marker Therapeutics, Inc. there?
Today Marker Therapeutics, Inc. has the market capitalization of ‪33.91 M‬, it has increased by 24.94% over the last week.
Yes, you can track Marker Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Marker Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
MRKR earnings for the last quarter are −0.26 USD per share, whereas the estimation was −0.39 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.28 USD per share. See more details about Marker Therapeutics, Inc. earnings.
Marker Therapeutics, Inc. revenue for the last quarter amounts to ‪1.93 M‬ USD, despite the estimated figure of ‪1.00 M‬ USD. In the next quarter, revenue is expected to reach ‪1.00 M‬ USD.
MRKR net income for the last quarter is ‪−2.31 M‬ USD, while the quarter before that showed ‪−2.19 M‬ USD of net income which accounts for −5.27% change. Track more Marker Therapeutics, Inc. financial stats to get the full picture.
No, MRKR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 8.00 employees. See our rating of the largest employees — is Marker Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Marker Therapeutics, Inc. EBITDA is ‪−10.19 M‬ USD, and current EBITDA margin is −440.37%. See more stats in Marker Therapeutics, Inc. financial statements.
Like other stocks, MRKR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Marker Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Marker Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Marker Therapeutics, Inc. stock shows the sell signal. See more of Marker Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.